Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Increase in mRNA Level of Orexin1 and 2 Receptors Following Induction of Experimental Autoimmune Encephalomyelitis in Mice.
Apitope Announces Positive Results from Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis
B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.
Glycine receptor and myelin oligodendrocyte glycoprotein antibodies in Turkish patients with neuromyelitis optica.
Combination Treatment of Interferon β-1b and Warfarin for a Patient With Baló's Concentric Sclerosis and Antiphospholipid Syndrome.
Differential effects of fingolimod on B-cell populations in multiple sclerosis.
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).
Epidemiology of Neuromyelitis Optica in the United States: A Multicenter AnalysisEpidemiology of NMO.
Phase II Cladribine Add-on to Interferon-beta (IFN-b) Therapy in MS Subjecs With Active Disease (ONWARD)
[Intractable vomiting as first manifestation of neuromyelitis Optica.]
Gut microbiota composition and relapse risk in pediatric MS: A pilot study.
Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1R ) and receptor-5 (S1P5R ) agonist with autoimmune disease-modifying activity.
Puma, but not noxa is essential for oligodendroglial cell death.
Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3.
Treatment with 4-aminopyridine improves upper limb tremor of a patient with multiple sclerosis: a video case report.
Overcoming barriers in progressive multiple sclerosis research.
Predictive value of early brain atrophy on response in patients treated with interferon β.
Drak2 Does Not Regulate TGF-β Signaling in T Cells.
Cognitive impairment and cortical degeneration in neuromyelitis optica.
The history of the oxazaphosphorine cytostatics.
American Society for Cell Biology Annual Meeting
Rescue Therapy Using Rituximab for Multiple Sclerosis.
Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis.
Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection.

Pages